CU20230043A7 - Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3 - Google Patents

Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3

Info

Publication number
CU20230043A7
CU20230043A7 CU2023000043A CU20230043A CU20230043A7 CU 20230043 A7 CU20230043 A7 CU 20230043A7 CU 2023000043 A CU2023000043 A CU 2023000043A CU 20230043 A CU20230043 A CU 20230043A CU 20230043 A7 CU20230043 A7 CU 20230043A7
Authority
CU
Cuba
Prior art keywords
bispecific antibodies
ngcgm3
antibody
ganglioside
bind
Prior art date
Application number
CU2023000043A
Other languages
English (en)
Inventor
Matos Ana Karla Diego
García Tays Hernández
Gundram Jung
Monzón Kalet León
Iglesias Claudia Aracelis Plasencia
Latifa Zekri
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2023000043A priority Critical patent/CU20230043A7/es
Priority to TW113130630A priority patent/TW202523687A/zh
Priority to CN202480057026.1A priority patent/CN121794299A/zh
Priority to AU2024338945A priority patent/AU2024338945A1/en
Priority to KR1020267010609A priority patent/KR20260068097A/ko
Priority to EP24799477.5A priority patent/EP4775594A1/en
Priority to PCT/CU2024/050006 priority patent/WO2025051309A1/es
Priority to ARP240102346A priority patent/AR133720A1/es
Publication of CU20230043A7 publication Critical patent/CU20230043A7/es
Priority to MX2026002768A priority patent/MX2026002768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>La presente invención se relaciona con el campo de la Biotecnología y la Inmuno- oncología. Se describen anticuerpos biespecíficos que comprenden un anticuerpo, fragmento de anticuerpo o fragmento variable de cadena única que reconocen el gangliósido NGcGM3 en las células tumorales y un anticuerpo, fragmento de anticuerpo o fragmento variable de cadena única que reconocen al antígeno CD3 en células efectoras inmunes humanas. Estos anticuerpos biespecíficos se caracterizan por su capacidad de mediar citotoxicidad selectiva sobre células tumorales positivas al NGcGM3, y no a células normales que puedan expresar el gangliósido y permiten el reclutamiento no solo de linfocitos T, sino también de NKT. Los anticuerpos biespecíficos de la presente invención y los ácidos nucleicos que los codifican son útiles en el tratamiento de desórdenes linfoproliferativos y tumores sólidos que expresan el NGcGM3.<br /> </p>
CU2023000043A 2023-09-08 2023-09-08 Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3 CU20230043A7 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CU2023000043A CU20230043A7 (es) 2023-09-08 2023-09-08 Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3
TW113130630A TW202523687A (zh) 2023-09-08 2024-08-15 結合ＣＤ３及神經節苷脂ＮＧｃＧＭ３之雙特異性抗體
CN202480057026.1A CN121794299A (zh) 2023-09-08 2024-08-23 结合CD3和神经节苷脂NGcGM3的双特异性抗体
AU2024338945A AU2024338945A1 (en) 2023-09-08 2024-08-23 Bispecific antibodies that bind cd3 and the ganglioside ngcgm3
KR1020267010609A KR20260068097A (ko) 2023-09-08 2024-08-23 CD3 및 강글리오사이드 NGcGM3에 결합하는 이중특이적 항체
EP24799477.5A EP4775594A1 (en) 2023-09-08 2024-08-23 Bispecific antibodies that bind cd3 and the ganglioside ngcgm3
PCT/CU2024/050006 WO2025051309A1 (es) 2023-09-08 2024-08-23 ANTICUERPOS BIESPECÍFICOS QUE UNEN CD3 Y EL GANGLIÓSIDO NGcGM3
ARP240102346A AR133720A1 (es) 2023-09-08 2024-09-03 ANTICUERPOS BIESPECÍFICOS QUE UNEN CD3 Y EL GANGLIÓSIDO NGcGM3
MX2026002768A MX2026002768A (es) 2023-09-08 2026-03-06 Anticuerpos biespecificos que unen cd3 y el gangliosido ngcgm3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2023000043A CU20230043A7 (es) 2023-09-08 2023-09-08 Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3

Publications (1)

Publication Number Publication Date
CU20230043A7 true CU20230043A7 (es) 2025-04-04

Family

ID=93335404

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2023000043A CU20230043A7 (es) 2023-09-08 2023-09-08 Anticuerpos biespecíficos que unen cd3 y el gangliósido ngcgm3

Country Status (9)

Country Link
EP (1) EP4775594A1 (es)
KR (1) KR20260068097A (es)
CN (1) CN121794299A (es)
AR (1) AR133720A1 (es)
AU (1) AU2024338945A1 (es)
CU (1) CU20230043A7 (es)
MX (1) MX2026002768A (es)
TW (1) TW202523687A (es)
WO (1) WO2025051309A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
CN105530959B (zh) * 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
US9611325B2 (en) 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3

Also Published As

Publication number Publication date
AR133720A1 (es) 2025-10-29
KR20260068097A (ko) 2026-05-13
WO2025051309A1 (es) 2025-03-13
CN121794299A (zh) 2026-04-03
TW202523687A (zh) 2025-06-16
AU2024338945A1 (en) 2026-04-16
MX2026002768A (es) 2026-04-01
EP4775594A1 (en) 2026-07-15

Similar Documents

Publication Publication Date Title
Feldmann et al. Retargeting of T lymphocytes to PSCA-or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
HN2004000356A (es) Anticuerpos dirigidos a m-csf
CO2017011486A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
MX2021000488A (es) Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos.
PE20211867A1 (es) Anticuerpos biespecificos y su uso
MX2025000370A (es) Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
Molgora et al. Killing the invaders: NK cell impact in tumors and anti-tumor therapy
PY1794093A (es) Anticuerpo monoclonal o un fragmento de unión a antígeno dirigidos contra cd127
PE20200384A1 (es) Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos
PE20230160A1 (es) Anticuerpos especificos para cd47, pd-l1 y sus usos
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
GT200100257A (es) Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
FI3546572T3 (fi) Cd19-spesifinen kimeerinen antigeenireseptori ja sen käyttötapoja
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
AR123628A1 (es) Constructos anti-cd93 y usos de estos
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
FI3368571T3 (fi) Transformoivia kasvutekijä-beeta-vasteellisia polypeptidejä ja niiden käyttömenetelmiä
ECSP20039728A (es) Anticuerpos monoclonales y métodos para utilizar los mismos
CO6351802A2 (es) Anticuerpos para ccr2
SI2970447T1 (en) PROTITELES AGAINST PAN-ELR + CXC KEMOCIN
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.